Oxford BioTherapeutics
Oxford BioTherapeutics is a biotechnology company developing targeted cancer therapies and oncology treatments.
The UK Home Office lists Oxford BioTherapeutics as a licensed sponsor (A-rated, Global Business Mobility: Senior or Specialist Worker and Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. We're showing 2 of their current openings.
Sponsor licence details
Sourced from the UK Home Office register of licensed sponsors.
Sponsorship history
Certificates of Sponsorship Oxford BioTherapeutics assigned each year, from Home Office figures released under the Freedom of Information Act.
Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.
Licence timeline Pro
Every change we've seen on the Home Office register for Oxford BioTherapeutics, and what its recent adverts say about sponsorship.
See this employer's full licence history: when it was licensed, rating and route changes, and when it last offered sponsorship in an advert.
Unlock with ProAbout Oxford BioTherapeutics
Oxford BioTherapeutics is a clinical-stage oncology company that develops targeted cancer therapies. The business focuses on pioneering treatments such as antibody-drug conjugates, immuno-oncology therapies, t-cell engagers, and radiopharmaceuticals to improve outcomes for cancer patients globally.
The company utilises its proprietary database, which contains thousands of identified and quantified membrane proteins, to discover novel targets for antibody-based therapeutics. Through research and development sites, the firm analyses patient tissue, shortlists cancer-specific targets, and generates therapeutic antibodies and binders in partnership with other innovators in the healthcare sector.
Open roles
2 live positions matched to this sponsor licence.